Compare · CERS vs RDDT
CERS vs RDDT
Side-by-side comparison of Cerus Corporation (CERS) and Reddit Inc. (RDDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and RDDT operate in EDP Services (Technology), so they compete in similar markets.
- RDDT is the larger of the two at $32.93B, about 63.2x CERS ($521.0M).
- Over the past year, CERS is up 72.3% and RDDT is up 44.1% - CERS leads by 28.1 points.
- CERS has been more active in the news (12 items in the past 4 weeks vs 9 for RDDT).
- RDDT has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Reddit Inc.
- Price
- $2.55-2.11%
- $169.39-1.00%
- Market cap
- $521.0M
- $32.93B
- 1M return
- -2.49%
- +8.68%
- 1Y return
- +72.30%
- +44.15%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- 2024
- News (4w)
- 12
- 9
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Latest CERS
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Cerus Corporation Closes New Debt Facility of Up to $110 Million
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Lucena Ann was granted 60,000 shares, increasing direct ownership by 35% to 232,284 units (SEC Form 4)
- Director Bjerkholt Eric was granted 60,000 shares, increasing direct ownership by 27% to 282,133 units (SEC Form 4)
- Director Nachtsheim Jami K was granted 60,000 shares, increasing direct ownership by 29% to 268,362 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $50,001 worth of shares (16,667 units at $3.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1.00% to 1,656,707 units (SEC Form 4)
- Director Witney Frank was granted 60,000 shares, increasing direct ownership by 21% to 340,059 units (SEC Form 4)
- Director Gregory Dean A. was granted 60,000 shares, increasing direct ownership by 69% to 146,725 units (SEC Form 4)
- Director Shan Hua was granted 60,000 shares, increasing direct ownership by 45% to 192,386 units (SEC Form 4)
Latest RDDT
- CEO & President Huffman Steve Ladd exercised 18,000 shares at a strike of $25.29 and sold $3,134,316 worth of shares (18,000 units at $174.13) as part of a pre-agreed trading plan (SEC Form 4)
- Reddit to Present at the BofA Securities 2026 Global Technology Conference
- Chief Operating Officer Wong Jennifer L. covered exercise/tax liability with 38,112 shares, decreasing direct ownership by 4% to 1,050,339 units (SEC Form 4) to cover taxes
- CEO & President Huffman Steve Ladd converted options into 2,955 shares and covered exercise/tax liability with 40,336 shares (SEC Form 4) (tax liability)
- Chief Legal Officer Lee Benjamin Seong covered exercise/tax liability with 3,886 shares, decreasing direct ownership by 5% to 75,423 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Vollero Andrew covered exercise/tax liability with 10,320 shares, decreasing direct ownership by 4% to 244,208 units (SEC Form 4) (tax withholding)
- Chief Accounting Officer Reynolds Michelle Marie covered exercise/tax liability with 1,265 shares, decreasing direct ownership by 7% to 15,868 units (SEC Form 4) to satisfy withholding tax
- Chief Operating Officer Wong Jennifer L. exercised 39,167 shares at a strike of $5.35 and sold $6,208,842 worth of shares (39,167 units at $158.52) as part of a pre-agreed trading plan (SEC Form 4)
- CEO & President Huffman Steve Ladd exercised 18,000 shares at a strike of $25.29 and sold $2,828,744 worth of shares (18,000 units at $157.15) as part of a pre-agreed trading plan (SEC Form 4)
- /C O R R E C T I O N -- Fleet Device Management/